“Our process to evaluate potential corporate transactions, advised by Torreya a global investment bank specializing in life sciences, will continue in the fourth quarter given the importance of these near term milestones”
My guess is that Treagus is telling us the sale price is expected to go up with Orphan Drug Status and starting Ph3 for Retts..
Ann: Neuren approaching key milestones in Q4 2019, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.77 |
Change
-0.190(1.47%) |
Mkt cap ! $1.609B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.70 | $2.848M | 220.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 156 | $12.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.78 | 688 | 7 |
View Market Depth
| Last trade - 14.15pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |